X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (716) 716
Publication (171) 171
Patent (44) 44
Conference Proceeding (16) 16
Book Review (5) 5
Book / eBook (2) 2
Magazine Article (1) 1
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (290) 290
index medicus (282) 282
male (170) 170
female (168) 168
hematology (147) 147
middle aged (134) 134
aged (131) 131
oncology (122) 122
multiple myeloma (119) 119
adult (111) 111
bortezomib (68) 68
life sciences (63) 63
aged, 80 and over (62) 62
animals (61) 61
analysis (60) 60
multiple myeloma - drug therapy (60) 60
prognosis (57) 57
research (54) 54
survival (54) 54
treatment outcome (48) 48
multiple myeloma - pathology (47) 47
therapy (47) 47
cancer (45) 45
multiple-myeloma (45) 45
humanities and social sciences (44) 44
diagnosis (43) 43
physics (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (39) 39
mice (37) 37
abridged index medicus (36) 36
economics and finance (36) 36
multiple myeloma - mortality (35) 35
dexamethasone (34) 34
lenalidomide (33) 33
management (32) 32
thalidomide (31) 31
expression (30) 30
france (30) 30
medicine, general & internal (30) 30
retrospective studies (30) 30
data envelopment analysis (29) 29
stem-cell transplantation (29) 29
waldenstrom macroglobulinemia - drug therapy (29) 29
risk factors (28) 28
care and treatment (27) 27
transplantation (27) 27
usage (27) 27
chemotherapy (26) 26
survival analysis (26) 26
decontamination arrangements therefor (25) 25
dexamethasone - administration & dosage (25) 25
follow-up studies (25) 25
hematology, oncology and palliative medicine (25) 25
nuclear engineering (25) 25
nuclear physics (25) 25
patients (25) 25
protection against x-radiation, gamma radiation, corpuscularradiation or particle bombardment (25) 25
thalidomide - analogs & derivatives (25) 25
treating radioactively contaminated material (25) 25
waldenstrom macroglobulinemia - pathology (25) 25
antineoplastic agents - therapeutic use (24) 24
multiple myeloma - genetics (24) 24
recurrence (24) 24
time factors (24) 24
young adult (24) 24
efficiency (23) 23
studies (23) 23
survival rate (23) 23
adolescent (22) 22
monoclonal gammopathy (22) 22
prospective studies (22) 22
risk (21) 21
[shs.eco]humanities and social sciences/economies and finances (20) 20
cells (20) 20
disease progression (20) 20
economics (20) 20
bone marrow (19) 19
cell line, tumor (19) 19
disease-free survival (19) 19
gene expression (19) 19
growth (19) 19
health aspects (19) 19
international workshop (19) 19
medicine (19) 19
research article (19) 19
waldenstrom macroglobulinemia - genetics (19) 19
article (17) 17
chronic lymphocytic-leukemia (17) 17
drug therapy (17) 17
genetic aspects (17) 17
multidisciplinary sciences (17) 17
multiple myeloma - diagnosis (17) 17
myeloma (17) 17
operations research & management science (17) 17
rituximab (17) 17
stem cells (17) 17
thalidomide - administration & dosage (17) 17
kaplan-meier estimate (16) 16
leukemia (16) 16
lymphoma (16) 16
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (680) 680
French (106) 106
German (7) 7
Portuguese (2) 2
Spanish (2) 2
Chinese (1) 1
Korean (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncogene, ISSN 0950-9232, 01/2016, Volume 35, Issue 4, pp. 479 - 490
Waldenstrom macroglobulinemia (WM) is a proliferative disorder of IgM-secreting, lymphoplasmacytoid cells that inhabit the lymph nodes and bone marrow. The... 
SURVIVAL | ACTIVATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIM | ESTABLISHMENT | BCL-X(L) | CELL-DEATH | CELL BIOLOGY | ONCOLOGY | LINE | GENETICS & HEREDITY | MITOCHONDRIAL DYSFUNCTION | BAX | MYELOMA | Apoptosis - drug effects | Humans | Gene Expression Regulation, Neoplastic | bcl-2 Homologous Antagonist-Killer Protein - genetics | MicroRNAs - metabolism | Cell Line, Tumor - drug effects | Bortezomib - pharmacology | bcl-2 Homologous Antagonist-Killer Protein - metabolism | Waldenstrom Macroglobulinemia - pathology | Proto-Oncogene Proteins c-bcl-2 - metabolism | Waldenstrom Macroglobulinemia - drug therapy | Bcl-2-Like Protein 11 | Biphenyl Compounds - pharmacology | Nitrophenols - pharmacology | Forkhead Transcription Factors - metabolism | Apoptosis Regulatory Proteins - genetics | Membrane Proteins - metabolism | bcl-2-Associated X Protein - genetics | Proto-Oncogene Proteins - metabolism | Membrane Proteins - genetics | bcl-2-Associated X Protein - metabolism | Proto-Oncogene Proteins - genetics | Waldenstrom Macroglobulinemia - metabolism | Forkhead Transcription Factors - genetics | Multiple Myeloma - metabolism | Sulfonamides - pharmacology | Piperazines - pharmacology | Apoptosis Regulatory Proteins - metabolism | Multiple Myeloma - pathology | MicroRNAs - genetics | Apoptosis - physiology | Forkhead Box Protein O3 | Proto-Oncogene Proteins c-bcl-2 - genetics | Multiple Myeloma - genetics | Waldenstrom Macroglobulinemia - genetics | Apoptotic proteins | Development and progression | Genetic aspects | Cellular signal transduction | Gene expression | Health aspects | Macroglobulinemia | Proteins | Bone marrow | Lymphomas | Mutation | Cellular biology | apoptosis | Waldenström Macroglobulinemia | miR-155 | Bcl-2 family
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 18, pp. 2347 - 2357
Purpose The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone... 
ZOLEDRONIC ACID | ONCOLOGY | VERTEBRAL AUGMENTATION | SKELETAL-RELATED EVENTS | UNDETERMINED SIGNIFICANCE | DOUBLE-BLIND | MONOCLONAL GAMMOPATHY | RANDOMIZED CONTROLLED-TRIAL | CLINIC CONSENSUS STATEMENT | SPINAL-CORD COMPRESSION | VITAMIN-D DEFICIENCY | Outcome Assessment (Health Care) - methods | Humans | Imidazoles - administration & dosage | Tomography, X-Ray Computed | Positron-Emission Tomography | Fractures, Bone - diagnosis | Medical Oncology - organization & administration | Multiple Myeloma - drug therapy | Bone Diseases - drug therapy | Diphosphonates - therapeutic use | Imidazoles - therapeutic use | Drug Therapy, Combination | Osteonecrosis - diagnosis | Bone Diseases - complications | Multiple Myeloma - complications | Bone Density Conservation Agents - therapeutic use | Bone Diseases - radiotherapy | Combined Modality Therapy | Diphosphonates - administration & dosage | International Cooperation | Bone Density Conservation Agents - administration & dosage | Magnetic Resonance Imaging | Administration, Intravenous | Radiotherapy - methods | Clodronic Acid - therapeutic use | Clodronic Acid - administration & dosage | Multiple Myeloma - radiotherapy | Osteonecrosis - prevention & control | Fractures, Bone - prevention & control | Practice Guidelines as Topic | Index Medicus | Hema20 | Gdln2 | Bone5 | Special | Hema23 | Hema22 | Hema21
Journal Article
British Journal of Haematology, ISSN 0007-1048, 01/2013, Volume 160, Issue 2, pp. 171 - 176
Journal Article
Journal Article
Acta Astronautica, ISSN 0094-5765, 2005, Volume 56, Issue 4, pp. 453 - 464
This paper reviews both the thermo-mechanical architecture and the configuration of the thermal protection system (IPS) of the Pre-X vehicle, as presented at... 
ENGINEERING, AEROSPACE
Journal Article
Journal Article
by Ogawa, H and Koyanagi, R and Kawada-Watanabe, E and Yamaguchi, J and Takagi, A and Hagiwara, N and Deedwania, P. C and Demicco, D. A and Breazna, A and Wun, C. C and Pedersen, T and Colhoun, H. M and Neil, A and Hitman, G and Nakanishi, K and Fukuda, S and Shimada, K and Ehara, S and Inanami, H and Matsumoto, K and Taguchi, H and Muro, T and Yoshikawa, J and Yoshiyama, M and Dimitriadis, K and Tsioufis, C and Tatsis, I and Chlapoutakis, G and Lioni, L and Tzamou, V and Kasiakogias, A and Thomopoulos, C and Tousoulis, D and Stefanadis, C and Terentes-Printzios, D and Vlachopoulos, C and Aznaouridis, K and Ioakeimidis, N and Parapid, B and Vukcevic, V and Obrenovic-Kircanski, B and Simic, D. V and Milic, N. M and Stojanov, V and Beleslin, B and Nedeljkovic, I and Nedeljkovic-Arsenovic, O. M. S and Ostojic, M. C and Kotecha, D and Krum, H and New, G and Eccleston, D and Collins, P and Flather, M and Pepper, J and Tomiyama, H and Odaira, M and Yoshida, M and Shiina, K and Matsumoto, C and Yamashina, A and Pastormerlo, L. E and Maffei, S and Chubuchny, V and Mazzone, A. M and Susini, C and Passino, C and Chiappino, D and Emdin, M and Clerico, A and Katsi, V and Souretis, G and Vlasseros, I and Vrachatis, D and Kallikazaros, I and Androulakis, E and Chatzistamatiou, E and Papageorgiou, N and Miliou, A and Siasos, G and Moustakas, G and Ochoa, J. E and Balparda, J. K and Correa, M. M and Valencia, A. M and Alvarez, M and Mcewen, J. G and Bilo, G and Salvi, P and Aristizabal, D and Parati, G and De Vries, H and Engen-Verheul, M and Kemps, H. M. C and Kraaijenhagen, R and Peek, N and Vervueren, P. L and Bongard, V and Arveiler, D and Dallongeville, J and ... and on behalf of GEMI Group and on behalf of Korean Acute Myocardial Infarction Registry and on behalf of SWEETHEART-Study-Group and on behalf of QuIK Steering Committee and on behalf of On Behalf of the MADIT-CRT Investigators and on behalf of NAGOYA HEART Study Group and on behalf of Kan Wang, Xiaosheng Hu, Changqing Du, Shike Tu, Furong Zhang, and Xudong Xie and on behalf of The FRANCE2 scientific Committee and on behalf of Oslo Ischemia Study Group and on behalf of EUROVISION investigators and on behalf of German transcatheter aortic valve interventions registry and on behalf of Tokyo CCU network Committee and on behalf of Neha Singh and on behalf of the CASE-J Ex Study Group and on behalf of On behalf of Preserved-DATA-HELP (Diagnostic And TherApeutic methods, used in patients with systolic HEart failure, Living in Poland) investigators and on behalf of Associazione per lo Studio della Trombosi in Cardiologia and on behalf of BRAVO Investigators and on behalf of TIMI Study Group and on behalf of The Swedish Heart Failure Registry and on behalf of German Competence Network of Heart Failure and on behalf of Nordic ARVC Registry and on behalf of ACUITY and HORIZONS AMI and on behalf of Biomarkers in Cardiology and on behalf of Portuguese Registry of Acute Coronary Syndromes Investigators and on behalf of IMPROVE study group and on behalf of CLARICOR and on behalf of Department of Cardiology, Jinan Central Hospital Affiliated to Shandong University and on behalf of STAR-Study-Group and on behalf of DiaRegis-Study-Group and on behalf of MASS II Trial and on behalf of The Rotterdam Study and on behalf of the Korea Acute Myocardial Infarction Registry and on behalf of SACRA and PLUM registries investigators and on behalf of SMILE-4 and on behalf of AMIS Plus Investigators and on behalf of Gutenberg Heart Study and on behalf of VIPER-BP Study Investigators and on behalf of Hypersleep and on behalf of The CHART-2 Investigators and on behalf of HIJ-CREATE and on behalf of Joint "Croix Rouge Francaise" and "Federation Francaise de Cardiologie" Study Investigators and on behalf of ACTION and on behalf of EHS-PCI-Registry Study Group and on behalf of CCMR-3B Study Investigators and on behalf of The EURIKA investigators and on behalf of The GARFIELD Investigators and on behalf of a name and on behalf of RESET study investigators and on behalf of the SchlaHF-Investigators and on behalf of VIPER-BP Investigators and on behalf of ISSUE3 investigators and on behalf of FOCUS registry investigators and on behalf of NEO study and on behalf of cardiology unit, Ramathibodi hospital and on behalf of First Division of Cardiovascular Department, Chang Gung Memorial Hospital, Linkou and on behalf of Kyoto University/Canon joint research project and on behalf of The REACH registry investigators and on behalf of GCKD Study Investigators and on behalf of College National des Cardiologues des Hopitaux francais and on behalf of BBK registry Bad Krozingen and on behalf of PL-ACS Investigators and on behalf of the Three-City study Group and on behalf of Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation and on behalf of ARISTOTLE Investigators and Committees and on behalf of Heart Cycle and on behalf of Electrophysiologist International Community "EPIC" Alliance and on behalf of MOMOTARO study and on behalf of BOREAS-TCM study and on behalf of BIOSOLVE-I Investigators and on behalf of On behalf of DATA-HELP study (Diagnostic And TherApeutic methods, used in patients with systolic HEart failure, Living in Poland) investigators and on behalf of FINN-AKVA study group
European Heart Journal, ISSN 0195-668X, 08/2012, Volume 33, Issue suppl 1, pp. 655 - 939
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 02/2014, Volume 57, Issue 3, pp. 903 - 920
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 12/2012, Volume 39, Issue 12, pp. 1839 - 1847
Locally advanced head and neck squamous cell carcinoma (HNSCC) has a high rate of recurrence. Induction chemotherapy with DCF (docetaxel, cisplatin,... 
Early therapeutic assessment | Induction chemotherapy | Medicine & Public Health | 18 F-Fluorodeoxyglucose positron emission tomography | Orthopedics | Oncology | Head and neck squamous cell carcinoma | Prediction of survival | Nuclear Medicine | Imaging / Radiology | Cardiology | F-Fluorodeoxyglucose positron emission tomography | PATHOLOGICAL RESPONSE | CHEMORADIOTHERAPY | FLUOROURACIL | BREAST-CANCER | F-18-Fluorodeoxyglucose positron emission tomography | POSITRON-EMISSION-TOMOGRAPHY | INTERNATIONAL WORKSHOP | UNRESECTABLE HEAD | COST-UTILITY | PROGRESSION-FREE | LYMPHOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Induction Chemotherapy | Male | Tomography, X-Ray Computed | Carcinoma, Squamous Cell - diagnostic imaging | Positron-Emission Tomography | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Multimodal Imaging | Taxoids - therapeutic use | Squamous Cell Carcinoma of Head and Neck | Fluorouracil - administration & dosage | Neoplasm Recurrence, Local - diagnostic imaging | Female | Radiopharmaceuticals | Head and Neck Neoplasms - diagnostic imaging | Docetaxel | Head and Neck Neoplasms - drug therapy | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fluorodeoxyglucose F18 | Aged | Tomography | Nuclear medicine | Chemotherapy | Head & neck cancer | Medical prognosis | Index Medicus | Cell survival | Prognosis | Statistical analysis | 5-Fluorouracil | Best disease | Cisplatin | Metabolic response | Computed tomography | Head and neck cancer | Age | Acute toxicity | squamous cell carcinoma | Life Sciences | Human health and pathology
Journal Article
Journal Article